ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$3.95
+0.07 (+1.80%)
Open$3.90
Previous Close$3.88
Day High$4.02
Day Low$3.84
52W High$4.60
52W Low$1.35
Volume—
Avg Volume1.30M
Market Cap299.61M
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+206.1% upside
Current
$3.95
$3.95
Target
$12.09
$12.09
$9.42
$12.09 avg
$15.53
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |
| Rev Growth | +12.9% | -8.9% | -3.6% |
| Debt/Equity | 0.35 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |